New Analytic Tools for aHUS and C3G Diagnosis

Launched by MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH · Aug 2, 2023

Keywords

ClinConnect Summary

This clinical trial, part of a larger project called COMPRare, is focused on improving the diagnosis and treatment of rare kidney diseases known as aHUS (atypical Hemolytic Uremic Syndrome) and C3G (C3 Glomerulopathy). Researchers from seven European countries are working together to develop new tools that can help doctors identify these conditions more quickly and accurately. This project aims to find specific markers in the blood that can indicate how severe the disease is and how well treatment is working, which can lead to more personalized care for patients.

To participate in this trial, individuals must have a confirmed diagnosis of either C3G or aHUS. Patients with C3G, including both children and adults, are eligible if they provide consent to use their samples for research. For those with aHUS, they can join if they are in the early stages of the disease (before starting treatment) or in remission while receiving standard treatment. However, individuals with certain other conditions or recent treatments may not be eligible. Participants can expect to undergo various tests and assessments to help researchers understand their disease better, which will ultimately contribute to developing better treatment options for these conditions.

Gender

ALL

Eligibility criteria

• • Aim 1
• Inclusion Criteria:
• • Male and female patients (children and adults) with C3G diagnosis
• • Biobank written informed consent
• • Aim 2 Inclusion criteria
• • Male and female patients (children and adults) with aHUS diagnosis in acute phase (before any treatment), or in remission either untreated or undergoing anti-C5 treatment at standard dosing
• • Written informed consent Exclusion criteria
• • Stx-associated HUS
• • TTP (ADAMTS13\<10%)
• • Plasma therapy within 2 weeks from blood sampling